Table 4.
Sensitivity analysis on the association between baseline SUA/Scr with all-cause and cardiovascular mortality in CAPD patients.
| Outcomes | Model 5 SHR (95% CI) |
Model 6 HR (95% CI) |
Model 7 HR (95% CI) |
|---|---|---|---|
| All-cause mortality | |||
| SUA/Scr ratio per 1 SD increase | 1.585 (1.371, 1.833) | 1.725 (1.472, 2.022) | 1.556 (1.335, 1.813) |
| Quartiles of SUA/Scr ratio | |||
| Q1, ≤0.59 | Ref | Ref | Ref |
| Q2, 0.60–0.79 | 1.103 (0.826, 1.472) | 1.034 (0.738, 1.448) | 1.192 (0.873, 1.630) |
| Q3, 0.80–1.04 | 1.367 (1.035, 1.804) | 1.172 (0.852, 1.612) | 1.267 (0.937, 1.713) |
| Q4, ≥1.05 | 2.301 (1.755, 3.016) | 2.309 (1.709, 3.119) | 2.230 (1.666, 2.986) |
| p Value for trends | <.001 | <.001 | <.001 |
| Cardiovascular mortality | |||
| SUA/Scr ratio per 1 SD increase | 1.671 (1.384, 2.016) | 1.996 (1.634, 2.437) | 1.688 (1.414, 2.015) |
| Quartiles of SUA/Scr ratio | |||
| Q1, ≤0.59 | Ref | Ref | Ref |
| Q2, 0.60–0.79 | 1.108 (0.700, 1.753) | 1.019 (0.603, 1.722) | 1.165 (0.717, 1.894) |
| Q3, 0.80–1.04 | 2.252 (1.492, 3.399) | 1.856 (1.176, 2.931) | 2.025 (1.321, 3.104) |
| Q4, ≥1.05 | 3.501 (2.308, 5.311) | 3.686 (2.375, 5.720) | 3.385 (2.223, 5.156) |
| p Value for trends | <.001 | <.001 | <.001 |
SUA: serum uric acid; Scr: serum creatinine; Q: quartiles; SD: standard deviation; HR: hazard ratio; CI: confidence interval; CAPD: continuous ambulatory peritoneal dialysis.
Model 5: sensitivity analysis using competing risk model; model 6: sensitivity analysis excluding individuals less than 2 years follow-up (n = 360); model 7: sensitivity analysis excluding individuals with diuretic or statin therapy at baseline (n = 401); models 5–7 were fully adjusted for age, sex, BMI, DM, hypertension, centers, protopathy, hemoglobin, serum albumin, cholesterol, triglycerides, LDL, HDL, hs-CRP, and medicine use (including CCB, α-blocker, β-blocker, ACEI/ARB, diuretic, statin, and aspirin).